Body mass index and functioning in long-term schizophrenia. Results of the DSP project

European Psychiatry

Volumn 22, Issue 5, 2007, Pages 313-318

  Salokangas, Raimo K R ^a   Honkonen, Teija ^b   Stengård, Eija ^c   Hietala, Jarmo ^d  

^a Turku Psychiatric Clinic   (Finland)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

Body mass index; Functioning; Gender; Long term schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; FEMALE; HEALTH BEHAVIOR; HOSPITAL DISCHARGE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SOCIAL INTERACTION;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CHRONIC DISEASE; FEMALE; FINLAND; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS; SOCIAL ADJUSTMENT; STATISTICS;

EID: 34547106307     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2006.10.001     Document Type: Article

References (24)

1. Alanen Y.O., Räkköläinen V., Laakso J., Rasimus R., and Kaljonen A. Towards need-specific treatment of schizophrenic psychoses (1986), Springer-Verlag, Heidelberg
2. Allison D.B., and Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62 Suppl 7 (2001) 22-31
3. Allison D.B., Fontaine K.R., Heo M., Mentore J.L., Cappelleri J.C., Chandler L.P., et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 60 (1999) 215-220
4. Angermeyer M.C., Kühn L., and Goldstein J.M. Gender and the course of schizophrenia: differences in treated outcomes. Schizophr Bull 16 (1990) 293-307
5. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., and Tollefson G.D. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62 (2001) 231-238
6. Endicott J., Spitzer R.L., Fleis J.L., and Cohen J. The Global Assessment Scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33 (1976) 766-771
7. Harman H.H. Modern factor analysis (1976), University of Chicago Press, Chicago
8. Horrobin D.F. The membrane phospholibid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 30 (1998) 193-208
9. Kay S.R., Opler L.A., and Fiszbein A. Positive and negative syndrome scale (PANSS) rating manual (1986), Bronx Psychiatric Center, Bronx
10. Kinon B.J., Basson B.R., Gilmore J.A., and Tollefson G.D. Long-term olanzepine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62 (2001) 92-100
11. Leung A., and Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl 401 (2000) 3-38
12. Lieberman J., Chakos M., Wu H., Alvir J., Hoffman E., Robinson D., et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 49 (2001) 487-499
13. McElroy S.L., Kotwal R., Malhotra S., Nelson E.B., Keck P.E., and Nemeroff C.B. Are mood disorders and obesity related? A review for the mental health professionals. J Clin Psychiatry 65 (2004) 634-651
14. Melkersson K.I., Hulting A.L., and Brismar K.E. Elevated levels of insulin, leptin, and blood lipids in olanzepine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61 (2000) 742-749
15. Meltzer H.Y., Perry E., and Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 59 (2003) 19-27
16. Murray R.M., and Van Os J. Predictors of outcome in schizophrenia. J Clin Psychopharmacol 18 Suppl 1 (1998) 2S-4S
17. Myers A., and Rosen J. Obesity stigmatization and coping: relation to mental health symptoms, body image, and self-esteem. Int J Obes Relat Metab Disord 23 (1999) 221-230
18. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
19. Salokangas R.K.R., Honkonen T., Stengård E., and Koivisto A.-M. Symptom dimensions and their association with outcome and treatment setting in long-term schizophrenia. Results of the DSP project. Nord J Psychiatry 56 (2002) 319-327
20. Salokangas R.K.R., Stengård E., Honkonen T., Koivisto A.-M., and Saarinen S. Sairaalasta yhteiskuntaan. Seurantatutkimus sairaalasta kotiuttamisen vaikutuksista skitsofreniapotilaan elämään ja hoitotilanteeseen. (In Finnish) (2000), STAKES, Helsinki Raportteja 248
21. Salokangas R.K.R. Symptom dimensions and outcome in schizophrenia. World Psychiatry 2 (2003) 172-178
22. Salokangas R.K.R. Prognostic implications of the sex of schizophrenic patients. Br J Psychiatry 142 (1983) 145-151
23. Seeman M.V. Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand 73 (1986) 609-617
24. Taylor D.M., and McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 101 (2000) 416-432